Combination of invasive aspergillosis and mucormycosis in children: a case report and the results of a multicenter study
暂无分享,去创建一个
M. Belogurova | Y. Dinikina | O. Shadrivova | S. Ignatyeva | T. Bogomolova | N. Klimko | E. Boychenko | S. Khostelidi | M. Popova | A. G. Volkova | A. Kolbin | E. Shagdileeva | L. S. Zubarovskaya | Y. Avdeenko
[1] P. Escribano,et al. Correction: Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates , 2020, PloS one.
[2] A. Veselov. The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies , 2020 .
[3] C. Jung,et al. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level , 2020, Mycoses.
[4] J. Perfect,et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] E. Roilides,et al. Escmid-ecmm guideline: diagnosis and management of invasive aspergillosis in neonates and children. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[6] A. Chakrabarti,et al. PS1284 GLOBAL GUIDELINE FOR THE DIAGNOSIS AND MANAGEMENT OF MUCORMYCOSIS: AN INITIATIVE OF THE ECMM IN COOPERATION WITH THE MSG ERC , 2019, HemaSphere.
[7] A. Attarbaschi,et al. Incidence and Outcome of Invasive Fungal Diseases in Children With Hematological Malignancies and/or Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Study , 2019, Front. Microbiol..
[8] B. Afanasyev,et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. , 2019, Medical mycology.
[9] J. Donnelly,et al. New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies , 2019, Journal of fungi.
[10] B. Phillips,et al. Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review , 2018, Journal of the Pediatric Infectious Diseases Society.
[11] Л. С. Зубаровская,et al. Сочетание инвазивного аспергиллеза и мукормикоза у онкогематологических больных , 2018 .
[12] G. Ottaviani,et al. Combined Orofacial Aspergillosis and Mucormycosis: Fatal Complication of a Recurrent Paediatric Glioma—Case Report and Review of Literature , 2016, Mycopathologia.
[13] Sung‐Han Kim,et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[14] A. Guarascio,et al. Review of the New Delayed‐Release Oral Tablet and Intravenous Dosage Forms of Posaconazole , 2015, Pharmacotherapy.
[15] A. Kolbin,et al. Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia , 2014, Mycoses.
[16] L. Pagano,et al. SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients , 2013, Infection.
[17] S. Alexander,et al. Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data , 2012, Pediatric blood & cancer.
[18] M. Godoy,et al. Reversed halo sign: high-resolution CT scan findings in 79 patients. , 2012, Chest.
[19] C. Elie,et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] P. Hamal,et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[21] S. Y. Park,et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients , 2010, Transplant infectious disease : an official journal of the Transplantation Society.
[22] J. Sivik,et al. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up , 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[23] G. Socié,et al. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.
[24] J. Mehta,et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy , 2007, Bone Marrow Transplantation.
[25] D. Day,et al. Pulmonary fungal infections after bone marrow transplantation , 2006, Pediatric Radiology.
[26] W. Leisenring,et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] B. Gibson,et al. Mixed pulmonary fungal infection with Aspergillus fumigatus and Absidia corymbifera in a patient with relapsed acute myeloid leukaemia , 2005, British journal of haematology.
[28] F. Marty,et al. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. , 2004, The New England journal of medicine.
[29] M. Sande,et al. Simultaneous disseminated aspergillosis and zygomycosis in a leukemic patient. , 1979, Southern medical journal.